The Antibody and BioResource (ABR) Core contributes broadly to the basic and translational mission of the Center by focusing on two tools central to rigorous and reproducible biomedical research: ...

RubrYc’s lead programs include RTX-002, an anti-PD-1 agonist for serious autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis, and RTX-003, an anti-CD25 antibody that ...

The burden of drafting patent applications with sufficient support for antibody claims is not likely to lessen any time soon. The courts and the scientific community are in agreement that antibody ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special purpose acquisition company (SPAC) model to hop onto the Nasdaq.